Michael S. Gordon - 25 Jul 2025 Form 4 Insider Report for ProMIS Neurosciences Inc. (PMN)

Reporting relationship: 10%+ Owner
Issuer ticker: PMN
Reported as of: 25 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 Jul 2025, 20:20:23 UTC
Prior SEC filing: 02 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Michael S. Gordon

Key filing fact

Michael S. Gordon filed Form 4 for ProMIS Neurosciences Inc. (PMN) on 29 Jul 2025.

Key facts

This page summarizes Michael S. Gordon's Form 4 filing for ProMIS Neurosciences Inc. (PMN).
7 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 29 Jul 2025, 20:20.

Change

Previous filing in this sequence was filed on 02 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001034608 Primary reporting owner

GORDON MICHAEL S

Relationship: 10%+ Owner
Address: C/O TROVE,, 40 BROAD STREET, 8TH FLOOR, BOSTON
Signature: /s/ Michael S. Gordon
Signature date: 29 Jul 2025

This filing has been restated. Open the amended filing.

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PMN transaction

Common Shares, no par value

Exercise of in-the-money or at-the-money derivative security

Transaction value
Shares: +119,800
Change %: +5.8%
Price
Shares after: 2,195,429
Date: 25 Jul 2025
Ownership: By Title 19 Promis
Footnotes: F1, F2

PMN transaction

Common Shares, no par value

Exercise of in-the-money or at-the-money derivative security

Transaction value
Shares: +119,800
Change %: +5.5%
Price
Shares after: 2,315,229
Date: 25 Jul 2025
Ownership: By Title 19 Promis
Footnotes: F2, F3

PMN transaction

Common Shares, no par value

Exercise of in-the-money or at-the-money derivative security

Transaction value
Shares: +119,800
Change %: +5.2%
Price
Shares after: 2,435,029
Date: 25 Jul 2025
Ownership: By Title 19 Promis
Footnotes: F2, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PMN transaction Derivative

Tranche A Common Share Purchase Warrants

Exercise of in-the-money or at-the-money derivative security

Transaction value: $0
Shares: -119,800
Change %: -26%
Price: $0.000000
Shares after: 345,316
Date: 25 Jul 2025
Ownership: See footnote
Underlying class: Common Shares
Underlying amount: 119,800
Exercise price
Footnotes: F1, F2

PMN transaction Derivative

Tranche B Common Share Purchase Warrants

Exercise of in-the-money or at-the-money derivative security

Transaction value: $0
Shares: -119,800
Change %: -26%
Price: $0.000000
Shares after: 345,316
Date: 25 Jul 2025
Ownership: See footnote
Underlying class: Common Shares
Underlying amount: 119,800
Exercise price
Footnotes: F2, F3

PMN transaction Derivative

Tranche C Common Share Purchase Warrants

Exercise of in-the-money or at-the-money derivative security

Transaction value: $0
Shares: -119,800
Change %: -26%
Price: $0.000000
Shares after: 345,316
Date: 25 Jul 2025
Ownership: See footnote
Underlying class: Common Shares
Underlying amount: 119,800
Exercise price
Footnotes: F2, F4

PMN transaction Derivative

Warrants to Purchase Common Shares

Purchase

Transaction value
Shares: +539,100
Change %
Price
Shares after: 539,100
Date: 29 Jul 2025
Ownership: See footnote
Underlying class: Common Shares
Underlying amount: 539,100
Exercise price
Footnotes: F2, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.

Footnote F2

By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.

Footnote F3

On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.

Footnote F4

On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029.

Footnote F5

On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .